Abstract
Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis.
Highlights
The prevalence of non-alcohol-related fatty liver disease (NAFLD) varies between 19% and 33% in di erent populations
We propose registry-based randomised clinical trials or cohort multiple randomised clinical trials comparing interventions such as vitamin E, prebiotics/probiotics/synbiotics, polyunsaturated fatty acid (PUFA), and no nutritional supplementation
The reason for the choice of interventions is the impact of these interventions on indirect outcomes, which may translate to clinical benefit
Summary
The prevalence of non-alcohol-related fatty liver disease (NAFLD) varies between 19% and 33% in di erent populations. Prevalence of NAFLD varies between 19% and 33% in di erent populations, depending upon ethnicity, region of origin ( among people of similar ethnicity), overweight or obesity, and presence of other disorders such as diabetes mellitus or hypertension (Bedogni 2005; Park 2006; Dassanayake 2009; Koehler 2012; Lazo 2013; Fleischman 2014; Li 2014; Shen 2014; Nishioji 2015). Major risk factors associated with increased prevalence of NAFLD are obesity, being male, increasing age, ethnicity (e.g. Mexican-Americans have higher prevalence of fatty liver than other ethnic groups), genetic susceptibility (e.g. genetic variation in patatin-like phospholipase domain-containing 3 protein coding gene (PNPLA3)), hypertension, hypercholesterolaemia, diabetes mellitus, lower socio-economic level, lower-level educational attainment, poor sleep pattern, and lower physical activity (Bedogni 2005; Park 2006; Dassanayake 2009; Sookoian 2011; Koehler 2012; Lazo 2013; Fleischman 2014; Shen 2014; Bernsmeier 2015; Lonardo 2015)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
